Robot-assisted MRI/US transperineal target prostate biopsy with Biobot Mona Lisa 2.0: first experience in Europe

IF 6.9 2区医学 Q1 ONCOLOGY

Prostate Cancer and Prostatic Diseases Pub Date : 2026-02-25 DOI:10.1038/s41391-026-01094-8

Enrico Checcucci, Gabriele Bignante, Gabriele Volpi, Saverio Liguori, Paolo Alessio, Michele Sica, Michele Ortenzi, Daniele Amparore, Alessandra Saliva, Alberto Piana, Stefano De Luca, Alessandro Cerutti, Francesco Porpiglia

{"title":"Robot-assisted MRI/US transperineal target prostate biopsy with Biobot Mona Lisa 2.0: first experience in Europe","authors":"Enrico Checcucci, Gabriele Bignante, Gabriele Volpi, Saverio Liguori, Paolo Alessio, Michele Sica, Michele Ortenzi, Daniele Amparore, Alessandra Saliva, Alberto Piana, Stefano De Luca, Alessandro Cerutti, Francesco Porpiglia","doi":"10.1038/s41391-026-01094-8","DOIUrl":null,"url":null,"abstract":"The Mona Lisa 2.0 robotic platform integrates MRI/ultrasound fusion, AI-based prostate segmentation, and automated needle trajectory planning to optimize transperineal targeted biopsy (TB) precision. We report the first European experience in 10 consecutive patients undergoing robot-assisted TB, with optional systematic cores. Clinically significant prostate cancer was detected in all rTB procedures. Standard cores added limited diagnostic yield and mainly sampled perilesional “penumbra” areas. Mean biopsy duration was 12.9 min, no peri- or post-procedural complications occurred, and high-quality tissue samples were consistently obtained. These preliminary data confirm feasibility, safety, and reproducibility of Mona Lisa 2.0 robotic platform, as a new kid on the block in urologic robotic armamentarium.","PeriodicalId":20727,"journal":{"name":"Prostate Cancer and Prostatic Diseases","volume":"29 4","pages":"900-903"},"PeriodicalIF":6.9000,"publicationDate":"2026-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostate Cancer and Prostatic Diseases","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41391-026-01094-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The Mona Lisa 2.0 robotic platform integrates MRI/ultrasound fusion, AI-based prostate segmentation, and automated needle trajectory planning to optimize transperineal targeted biopsy (TB) precision. We report the first European experience in 10 consecutive patients undergoing robot-assisted TB, with optional systematic cores. Clinically significant prostate cancer was detected in all rTB procedures. Standard cores added limited diagnostic yield and mainly sampled perilesional “penumbra” areas. Mean biopsy duration was 12.9 min, no peri- or post-procedural complications occurred, and high-quality tissue samples were consistently obtained. These preliminary data confirm feasibility, safety, and reproducibility of Mona Lisa 2.0 robotic platform, as a new kid on the block in urologic robotic armamentarium.

查看原文本刊更多论文

机器人辅助MRI/US经会阴靶前列腺活检与Biobot蒙娜丽莎2.0：首次在欧洲的经验。

简介：蒙娜丽莎2.0机器人平台集成了MRI/超声融合、基于人工智能的前列腺分割和自动针头轨迹规划，以优化经会阴靶向活检（TB）的精度。病例介绍：我们报告了欧洲第一个连续10例患者接受机器人辅助结核病的经验，具有可选的系统核心。在所有rTB手术中均检测到具有临床意义的前列腺癌。标准岩心的诊断率有限，主要取样于病灶周围的“半影”区域。平均活检时间为12.9分钟，未发生术中或术后并发症，并始终获得高质量的组织样本。结论：这些初步数据证实了蒙娜丽莎2.0机器人平台作为泌尿外科机器人装备领域的新成员的可行性、安全性和可重复性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Prostate Cancer and Prostatic Diseases 医学-泌尿学与肾脏学

CiteScore

10.00

自引率

6.20%

发文量

142

审稿时长

6-12 weeks

期刊介绍： Prostate Cancer and Prostatic Diseases covers all aspects of prostatic diseases, in particular prostate cancer, the subject of intensive basic and clinical research world-wide. The journal also reports on exciting new developments being made in diagnosis, surgery, radiotherapy, drug discovery and medical management. Prostate Cancer and Prostatic Diseases is of interest to surgeons, oncologists and clinicians treating patients and to those involved in research into diseases of the prostate. The journal covers the three main areas - prostate cancer, male LUTS and prostatitis. Prostate Cancer and Prostatic Diseases publishes original research articles, reviews, topical comment and critical appraisals of scientific meetings and the latest books. The journal also contains a calendar of forthcoming scientific meetings. The Editors and a distinguished Editorial Board ensure that submitted articles receive fast and efficient attention and are refereed to the highest possible scientific standard. A fast track system is available for topical articles of particular significance.